Article
CXCR2 inhibition enables NASH-HCC immunotherapy
2022-02-25
Abstract excerpt
<h4>Objective</h4> Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data suggests NASH-HCC may be less sensitive to conventional immune checkpoint inhibition (ICI). We hypothesised that targeting neutrophils using a CXCR2 small molecule inhibitor may sensitise NASH-HCC to ICI therapy. <h4>Design</h4> Neutr...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 16a39b81-1c7c-56e3-b377-484d4dd5cc3a
- DOI
- 10.1101/2022.02.24.481779
